Baseline cytokines and programmed death-ligand 1 prognostic value in advanced gastric cancer with sintilimab plus chemotherapy

Table 3 Comparison of cytokine distribution with different clinical characteristics, n (%)

Characteristic	IL-4			IL-6			IL-8			IL-10			IL-17
	Low (n = 60)	High (n = 41)	P value	Low (n = 68)	High (n = 33)	P value	Low (n = 39)	High (n = 62)	P value	Low (n = 63)	High (n = 38)	P value	Low (n = 50)	High (n = 51)	P value
Age (year), median (Q1, Q3)	61.00 (52.00, 69.00)	66.00 (55.00, 71.00)	0.245	60.50 (51.75, 66.25)	66.00 (61.00, 79.00)	0.001	64.00 (54.00, 75.00)	61.50 (53.25, 69.00)	0.478	60.00 (50.50, 66.50)	66.00 (60.25, 75.50)	0.002	62.00 (54.00, 70.50)	65.00 (53.00, 70.00)	0.636
BMI (kg/m2), median (Q1, Q3)	21.63 (19.55, 22.90)	22.22 (20.31, 23.66)	0.225	21.79 (19.56, 23.18)	22.60 (20.31, 23.01)	0.498	22.22 (19.32, 23.18)	22.22 (20.11, 23.14)	0.485	22.22 (19.53, 23.18)	21.70 (20.31, 22.66)	0.872	21.70 (19.51, 22.76)	22.41 (19.83, 23.18)	0.392
ECOG			0.551			0.258			0.576			0.9			0.190
0	24 (40.00)	14 (34.15)		23 (33.82)	15 (45.45)		16 (41.03)	22 (35.48)		24 (38.10)	14 (36.84)		22 (44.00)	16 (31.37)
1	36 (60.00)	27 (65.85)		45 (66.18)	18 (54.55)		23 (58.97)	40 (64.52)		39 (61.90)	24 (63.16)		28 (56.00)	35 (68.63)
Sex			0.708			0.485			0.951			0.488			0.489
Male	33 (55.00)	21 (51.22)		38 (55.88)	16 (48.48)		21 (53.85)	33 (53.23)		32 (50.79)	22 (57.89)		25 (50.00)	29 (56.86)
Female	27 (45.00)	20 (48.78)		30 (44.12)	17 (51.52)		18 (46.15)	29 (46.77)		31 (49.21)	16 (42.11)		25 (50.00)	22 (43.14)
Tumor site			0.051			0.625			0.612			0.51			0.277
Stomach	53 (88.33)	30 (73.17)		55 (80.88)	28 (84.85)		33 (84.62)	50 (80.65)		53 (84.13)	30 (78.95)		39 (78.00)	44 (86.27)
Gastroesophageal junction	7 (11.67)	11 (26.83)		13 (19.12)	5 (15.15)		6 (15.38)	12 (19.35)		10 (15.87)	8 (21.05)		11 (22.00)	7 (13.73)
Stage			0.853			0.203			0.81			0.178			0.592
Local ate stage	8 (13.33)	6 (14.63)		12 (17.65)	2 (6.06)		5 (12.82)	9 (14.52)		11 (17.46)	3 (7.89)		6 (12.00)	8 (15.69)
Distant transfer	52 (86.67)	35 (85.37)		56 (82.35)	31 (93.94)		34 (87.18)	53 (85.48)		52 (82.54)	35 (92.11)		44 (88.00)	43 (84.31)
AFP			0.423			0.628			1			1			0.656
High	5 (8.33)	1 (2.44)		3 (4.41)	3 (9.09)		2 (5.13)	4 (6.45)		4 (6.35)	2 (5.26)		4 (8.00)	2 (3.92)
Normal	55 (91.67)	40 (97.56)		65 (95.59)	30 (90.91)		37 (94.87)	58 (93.55)		59 (93.65)	36 (94.74)		46 (92.00)	49 (96.08)
CEA			0.904			0.571			0.346			0.938			0.922
High	30 (50.00)	21 (51.22)		33 (48.53)	18 (54.55)		22 (56.41)	29 (46.77)		32 (50.79)	19 (50.00)		25 (50.00)	26 (50.98)
Normal	30 (50.00)	20 (48.78)		35 (51.47)	15 (45.45)		17 (43.59)	33 (53.23)		31 (49.21)	19 (50.00)		25 (50.00)	25 (49.02)
CA199			0.776			0.066			0.9			0.048			0.135
High	31 (51.67)	20 (48.78)		30 (44.12)	21 (63.64)		20 (51.28)	31 (50.00)		27 (42.86)	24 (63.16)		29 (58.00)	22 (43.14)
Normal	29 (48.33)	21 (51.22)		38 (55.88)	12 (36.36)		19 (48.72)	31 (50.00)		36 (57.14)	14 (36.84)		21 (42.00)	29 (56.86)
CA125			0.308			0.783			1			1			0.563
High	5 (8.33)	7 (17.07)		9 (13.24)	3 (9.09)		5 (12.82)	7 (11.29)		7 (11.11)	5 (13.16)		5 (10.00)	7 (13.73)
Normal	55 (91.67)	34 (82.93)		59 (86.76)	30 (90.91)		34 (87.18)	55 (88.71)		56 (88.89)	33 (86.84)		45 (90.00)	44 (86.27)
CA724			0.627			0.584			0.693			0.326			0.777
High	38 (63.33)	24 (58.54)		43 (63.24)	19 (57.58)		23 (58.97)	39 (62.90)		41 (65.08)	21 (55.26)		30 (60.00)	32 (62.75)
Normal	22 (36.67)	17 (41.46)		25 (36.76)	14 (42.42)		16 (41.03)	23 (37.10)		22 (34.92)	17 (44.74)		20 (40.00)	19 (37.25)
PD-L1			0.083			< 0.001			0.341			< 0.001			0.096
CPS < 5	9 (15.00)	12 (29.27)		4 (5.88)	17 (51.52)		10 (25.64)	11 (17.74)		4 (6.35)	17 (44.74)		7 (14.00)	14 (27.45)
CPS ≥ 5	51 (85.00)	29 (70.73)		64 (94.12)	16 (48.48)		29 (74.36)	51 (82.26)		59 (93.65)	21 (55.26)		43 (86.00)	37 (72.55)
EBV			1.000			1.000			0.229			0.709			0.282
No	55 (91.67)	38 (92.68)		63 (92.65)	30 (90.91)		38 (97.44)	55 (88.71)		59 (93.65)	34 (89.47)		48 (96.00)	45 (88.24)
Yes	5 (8.33)	3 (7.32)		5 (7.35)	3 (9.09)		1 (2.56)	7 (11.29)		4 (6.35)	4 (10.53)		2 (4.00)	6 (11.76)
MMR			0.599			0.859			0.333			0.484			1.000
pMMR	57 (95.00)	37 (90.24)		64 (94.12)	30 (90.91)		38 (97.44)	56 (90.32)		60 (95.24)	34 (89.47)		47 (94.00)	47 (92.16)
dMMR	3 (5.00)	4 (9.76)		4 (5.88)	3 (9.09)		1 (2.56)	6 (9.68)		3 (4.76)	4 (10.53)		3 (6.00)	4 (7.84)
Chemotherapy regimen			0.539			0.207			0.827			0.684			0.689
Platinum-doublet (SOX/XELOX)	27 (45.0)	21 (51.2)		30 (44.1)	10 (30.3)		18 (46.2)	30 (48.4)		31 (49.2)	17 (44.7)		25 (50.0%)	23 (45.1%)
Taxane- based	33 (55.0)	20 (48.8)		38 (55.9)	23 (69.7)		21 (53.8)	32 (51.6)		32 (50.8)	21 (55.3)		25 (50.0%)	28 (54.9%)

IL: Interleukin; BMI: Body mass index; ECOG: Eastern Cooperative Oncology Group; AFP: Alpha-fetoprotein; CEA: Carcinoembryonic antigen; CA: Carbohydrate antigen; PD-L1: Programmed death-ligand 1; CPS: Combined Positive Score; EBV: Epstein-Barr virus; MMR: Mismatch repair; dMMR: Deficient mismatch repair; pMMR: Proficient mismatch repair; SOX: Oxaliplatin + tegafur/gimeracil/oteracil; XELOX: Oxaliplatin + capecitabine.